A recent study published on September 18 in JAMA Network Open found that RSV vaccines for older adults are highly effective, reducing hospitalizations and deaths by about 80%. The research, based on data from 14.8 million Medicare-enrolled seniors, confirmed the high efficacy seen in clinical trials despite initial concerns about real-world performance. Both GlaxoSmithKline and Pfizer’s vaccines showed similar results, with further studies now focusing on whether booster shots are necessary to maintain immunity over time.
Written locally by qwen2.5:14b on 2026-09-21,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
In 2023, two new vaccines against respiratory syncytial virus (RSV), which kills thousands of older adults annually in the U.S., hit the market.
asserted
which → kill → market
As millions of people aged 60 and older received the shots, researchers watched and waited to see whether the efficacy numbers seen in clinical trials, which were quite high, would be mirrored in the real world.
asserted
which → age → world
“There was a little concern that maybe these vaccines will not turn out to be quite as potent as they appeared,” says Dr. Edward Walsh, a professor of medicine at the University of Rochester.
asserted
Walsh → be → Rochester
The trials had rolled out in the later phases of the COVID-19 pandemic, when there wasn’t as much RSV circulating as usual, which made some researchers wonder how later studies would play out.
asserted
studies → roll → pandemic
However, in a study published Sept. 18 in JAMA Network Open looking at 14.8 million seniors, researchers at the U.S. Food and Drug Administration found that the vaccines were highly effective, reducing the chances of an RSV-related hospitalization or death by around 80%.
asserted
vaccines → publish → %
Vaccines protect against RSV in older adults
asserted
Vaccines → protect → adults
Since the rollout, a handful of studies have looked at the effectiveness of these two vaccines, which are made by GlaxoSmithKline and Pfizer.
asserted
which → look → GlaxoSmithKline
“These have all—very interestingly, and comfortingly—really paralleled and mimicked the exact results of the efficacy trials,” says Walsh, who was not involved in the new study.
asserted
who → parallel → study
But this new work examines the entire U.S. population over 65 who are enrolled in Medicare, which is “vastly greater than the other studies,” he says.
asserted
he → examine → studies
In general, both vaccines performed similarly.
asserted
vaccines → perform → ?
The study found that people who received an RSV vaccine were more likely to live in affluent areas and more likely to have been vaccinated for flu and COVID, raising the question of whether their higher survival numbers have to do with access to health care.
asserted
numbers → find → care
However, when researchers performed an analysis meant to test for whether access to health care was a factor, the high efficacy of the RSV shot remained.
asserted
efficacy → perform → shot
“That was nice to see, that the data really was identical,” says Walsh.
asserted
Walsh → see → ?
Do people need RSV vaccine boosters?
asserted
people → need → boosters
One of the big questions now is whether and when to give people another shot, says Walsh.
asserted
Walsh → give → shot
Many of the people in the target population received them in the first year they were available, so much so that an RSV vaccine released in 2024, Moderna’s mRNA version, saw less uptake, he says.
asserted
he → receive → uptake
Would giving people another shot two or three years after their first refresh their immunity to the virus?
asserted
giving → give → virus
That’s a subject of active research.
asserted
That → ’ → research
The second time an RSV shot is given, “you don't get the same vigorous antibody response that you got when you gave the vaccine for the first time, and whether that is important, I don't think we really know,” Walsh says.
asserted
Walsh → give → time
(Flu vaccines, by contrast, require annual shots because strains change so much from year to year that this is the best way to get protected.)
asserted
this → require → year
Researchers will need to explore this in more detail before patients get a recommendation.
asserted
patients → need → recommendation
While this new study confirms that these RSV vaccines protect against the worst outcomes of the virus, work to develop vaccines against other viruses, such as parainfluenza, is ongoing.
asserted
work → confirm → parainfluenza
“It may very well be that the ultimate goal would be some sort of a respiratory vaccine that would cover multiple viruses,” Walsh speculates.
uncertain
Walsh → cover → viruses
“One of the thoughts is, well, maybe you can stimulate the innate immune system in a non-specific way such that it would prevent any viral infection.”
asserted
it → stimulate → infection
Working from the observation that having one virus often protects people from getting another, researchers have been delving into new ways of inducing immunity.
asserted
researchers → work → immunity
“These are the kinds of things that immunologists are thinking about,” he says.
asserted
he → think → that
The Aporia
